Cohance Lifesciences Releases Q3 FY26 Earnings Call Transcript
Cohance Lifesciences released the transcript of its Q3 FY26 earnings call. The company acknowledged performance below expectations due to portfolio mix and timing factors. While FY26 revenue declined, management reiterated commitment to the USD 1 billion sales target for FY30, anticipating FY27 growth.
The release of an earnings call transcript provides detailed information about the company's performance, challenges, and future outlook, which is material for investors to assess the company's financial health and strategic direction.
The announcement is a transcript release of an earnings call. While the company acknowledges below-expectation performance and provides explanations for challenges, it also reaffirms long-term targets and anticipates future growth, indicating a neutral sentiment.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has released the transcript of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, which followed a Board of Directors meeting on February 12, 2026, was conducted on February 12, 2026. The transcript provides detailed insights into the company's performance across its business segments, including Pharma CDMO, API Plus, and Specialty Chemicals.
During the call, the management acknowledged that recent performance has been below expectations, attributing it to a transition year driven by portfolio mix and customer-led timing factors. The Pharma CDMO business faced challenges such as destocking, patent expiry of a key molecule, and deferred customer reloads and scale-ups. However, the company highlighted deepening customer engagement with global innovators and progress in its advanced technology platforms like ADC and oligonucleotides.
The API Plus business was impacted by regulatory factors, including a warning letter for the Nacharam formulation site, and customer-related approval delays. Despite these, the company has focused on rebuilding its API and formulation pipeline with several DMF and ANDA filings. The Specialty Chemicals business saw progress in customer diversification and pipeline development, though near-term performance was affected by market conditions.
Financially, for the nine months ended December 31, 2025, revenue declined by 6.7% to ₹1,650 crore. Adjusted EBITDA decreased by 43% to ₹348 crore, with margins at 21%. The company reported a free cash flow of ₹175 crore for the period. Management reiterated its commitment to a USD 1 billion sales target for FY30, expecting FY27 to be a year of growth driven by a strong pipeline and recovery in the API Plus segment. The company also addressed the impact of the Nacharam facility's warning letter, stating that remediation actions are underway and production for non-US markets has resumed.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.